Medigen Biotechnology Corp. (TPEX:3176)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.50
-0.90 (-2.87%)
Apr 17, 2026, 1:30 PM CST
Market Cap4.25B -13.8%
Revenue (ttm)1.58B +15.3%
Net Income-108.80M
EPS-0.78
Shares Out139.31M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume393,850
Average Volume480,458
Open31.40
Previous Close31.40
Day's Range30.40 - 31.40
52-Week Range26.55 - 35.95
Beta0.26
RSI41.07
Earnings DateMay 13, 2026

About Medigen Biotechnology

Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1990
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 3176
Full Company Profile

Financial Performance

In 2025, Medigen Biotechnology's revenue was 1.58 billion, an increase of 15.28% compared to the previous year's 1.37 billion. Losses were -108.80 million, -46.84% less than in 2024.

Financial Statements